Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaJeffrey E. Lancet, Maria R. Baer, Ivana Gojo et al.|Leukemia|2010Cited by 155
OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)Rickin Popat, Nicholas Counsell, J Cavenagh et al.|St George's Online Research Archive (St George's University of London)|2017Cited by 0